Last reviewed · How we verify
Course A2 + Vin
Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies.
Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric lymphomas.
At a glance
| Generic name | Course A2 + Vin |
|---|---|
| Sponsor | Children's Cancer Group, China |
| Drug class | Combination chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen combines doxorubicin (a topoisomerase II inhibitor that intercalates DNA and prevents replication) with vincristine (a microtubule inhibitor that arrests cells in metaphase). The combination is designed to provide synergistic cytotoxic effects against rapidly dividing cancer cells in children. Course A2 typically refers to a specific protocol iteration used in pediatric oncology treatment schedules.
Approved indications
- Pediatric acute lymphoblastic leukemia (ALL)
- Pediatric lymphomas
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Cardiotoxicity
- Mucositis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Course A2 + Vin CI brief — competitive landscape report
- Course A2 + Vin updates RSS · CI watch RSS
- Children's Cancer Group, China portfolio CI